Compare BioNano Genomics Inc (BNGO) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Enphase Energy Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Enphase Energy Inc trades at $40.92 (market cap $5.59B). The key difference: Enphase Energy Inc is far larger — about 409.2× BioNano Genomics Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | ENPH | |
|---|---|---|
Market Cap | $13.66M | $5.59B |
Sector | Health | Technology |
52-Week High | $4.92 | $72.33 |
52-Week Low | $1.06 | $26.12 |
Enterprise Value | $16.26M | $5.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Enphase Energy (ENPH) trades at $41.06, up 0.34% with a bullish technical outlook supported by moving averages. The company reported mixed Q2 2026 earnings matching estimates but missing revenue expectations, with revenue declining 19.6% year-over-year. Recent developments include expanded battery system support and US manufacturing commitments. Valuation metrics show a P/E of 41.88 and P/S of 4.25, while profitability remains solid with 10.09% net income margin.
The stock presents recovery potential with analyst consensus target of $45.37 (10.5% upside), though faces headwinds from cyclical residential solar demand and competitive pressures. Key risks include execution challenges in European expansion and AI data center strategy, while institutional interest remains mixed with recent insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
